Cosmo Pharmaceuticals NV 2022 AR2
The report highlights Cosmo Pharmaceuticals' record financial performance in 2022, with revenues exceeding the ‑100 million threshold for the first time, reaching ‑102.1 million. Key achievements include the commercial success of Winlevi® as the most prescribed branded topical acne product in the U.S. and positive clinical trial results for the GI Genius™ intelligent endoscopy module. The company also expanded its commercial partnerships globally and progressed its clinical development pipeline, including starting a Phase I study for CB-03-10. Additionally, Cosmo established an ESG Committee to oversee its sustainability strategy, focusing on reducing its environmental footprint and promoting diversity and inclusion.
Company: Cosmo Pharmaceuticals NV
Sector: Manufacturing
Country: Ireland
Year: 2022
Type: AR2
Pages: 159
Cosmo Pharmaceuticals NV
The report highlights Cosmo Pharmaceuticals' record financial performance in 2022, with revenues exceeding the ‑100 million threshold for the first time, reaching ‑102.1 million. Key achievements include the commercial success of Winlevi® as the most prescribed branded topical acne product in the U.S. and positive clinical trial results for the GI Genius™ intelligent endoscopy module. The company also expanded its commercial partnerships globally and progressed its clinical development pipeline, including starting a Phase I study for CB-03-10. Additionally, Cosmo established an ESG Committee to oversee its sustainability strategy, focusing on reducing its environmental footprint and promoting diversity and inclusion.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women in Management
Employees